Yield Growth Corp Continues Push Towards Psychedelic Mushroom Investment Narrative

The Yield Growth Corp (CSE: BOSS) is continuing to push its recently announced psilocybin mushroom narrative. The firm announced today that they have obtain a number of recipes under their new mushroom-focused subsidiary, Flourish Mushroom Labs Inc. The recipes, of which there are nine in total, were acquired for 120,000 shares of Yield Growth at market prices on September 20 – roughly $32,000.

To be clear, the recipes that the firm acquired are for edible, legal mushrooms – types of which include Lion’s Mane, Turkey Tail, Reishi, and Shitake among others. However, Yield Growth is doing acrobatics to connect these edible mushroom recipes to that of the potential psilocybin, or “magic mushroom” market. The formulations are primarily for teas and soups.

These healthy edible mushroom formulations have the potential to be made with psilocybin mushrooms in jurisdictions where magic mushrooms are legal. We are pleased to add mushroom formulas to our extensive catalogue of cannabis formulas which are at various stages of commercialization.

Penny Green, CEO of Yield Growth Corp

The news release itself, while announcing that it had acquired recipes for items such as “chai latte green tea flavor mushroom tea,” “veggie mix for mushroom soup,” and “pumpkin spice mushroom elixir,” was primarily focused on psilocybin mushrooms – a potential new legal sector that some investors are hoping is as big as the “cannabis rush” that occurred over the past few years. The release identified a number of markets where the psychedelic mushrooms are legal, however Yield Growth didn’t indicate that it was actually interested in entering these markets.

It’s unclear when these new products will make it to market.

Yield Growth Corp is currently trading at $0.265 on the Canadian Securities Exchange.

Information for this briefing was found via Sedar and The Yield Growth Corp. The author has no securities or affiliations related to the discussed organizations. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.